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Abstract
Accurate analyses of the delayed effects of acute radiation exposure (DEARE) in survivors of the 
hematopoietic acute radiation syndrome (H-ARS) are hampered by low numbers of mice for 
examination due to high lethality from the acute syndrome, increased morbidity and mortality in 
survivors, high cost of husbandry for long-term studies, biological variability, and inconsistencies 
of models from different laboratories complicating meta-analyses. To address this, a compilation 
of 38 similar H-ARS studies conducted over a seven-year period in the authors’ laboratory, 
comprising more than 1,500 irradiated young adult C57BL/6 mice and almost 600 day-30 
survivors, was assessed for hematopoietic DEARE at various times up to 30 months of age. 
Significant loss of long-term repopulating potential of phenotypically-defined primitive 
hematopoietic stem cells (HSC) was documented in H-ARS survivors, as well as significant 
decreases in all hematopoietic lineages in peripheral blood, prominent myeloid skew, significantly 
decreased bone marrow cellularity and numbers of lineage-negative Sca-1+ cKit+ CD150+ cells 
(KSLCD150+; the phenotype known to be enriched for HSC), and increased cycling of 
KSLCD150+ cells. Studies interrogating the phenotype of bone marrow cells capable of initiation 
of suspension cultures and engraftment in competitive transplantation assays documented the 
phenotype of HSC in H-ARS survivors to be the same as that in non-irradiated age-matched 
controls. This compilation study adds rigor and validity to our initial findings of persistent 
hematopoietic dysfunction in H-ARS survivors that arises at the level of the HSC and which 
affects all classes of hematopoietic cells for the life of the survivor.
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INTRODUCTION
Exposure to potentially lethal high-dose radiation, from malicious activity or radiation 
accidents, results in the acute radiation syndromes (ARS). Bone marrow (BM) is the most 
sensitive tissue to radiation damage (Till and McCulloch 1961; Abramson et al. 1977; Visser 
et al. 1984; Jones et al. 1989; Jones et al. 1990; Keller and Snodgrass 1990; Hall 2000), 
owing to the highly proliferative nature of hematopoiesis driven by rare hematopoietic stem 
(HSC) and progenitor cells (HPC) that produce billions of blood cells daily to maintain 
homeostasis. HSC sustain life-long hematopoiesis and reconstitute normal BM functions 
following myelosuppression through two unique properties: 1) the ability to differentiate 
into all the formed elements of the blood, and 2) the ability to self-renew into daughter HSC 
(Till and McCulloch 1961; Visser et al. 1984; Jones et al. 1990; Keller and Snodgrass 1990). 
Whole-body exposures or significant partial-body exposures of 1–10 Gy in mice or up to 
approximately 6 Gy in humans result in the hematopoietic-ARS (H-ARS) due to loss of 
radiosensitive HSC/HPC (McCulloch and Till 1962; van Bekkum 1991; Inoue et al. 1995; 
Belkacemi et al. 2003) and death from infection and/or hemorrhage if left untreated 
(Coleman et al. 2003; Dainiak et al. 2003).
Survivors of the acute syndromes suffer later in life from the delayed effects of acute 
radiation exposure (DEARE) affecting multiple organ systems and which may result in 
fibrosis and loss of function in a stochastic dose-dependent manner. DEARE effects on the 
hematopoietic system are known as residual bone marrow damage (RBMD), a latent 
condition characterized by functionally compromised HSC and depressed hematopoiesis for 
years, most evident under stress (Botnick et al. 1979; Mauch et al. 1988; Chua et al. 2012; 
Chua et al. 2014) and hypothesized to be secondary to senescence (Hellman and Botnick 
1977; Meng et al. 2003; Wang et al. 2006; Wang et al. 2006). Neupogen (granulocyte-colony 
stimulating factor, G-CSF) and Neulasta (pegylated-G-CSF) were recently approved by the 
FDA for treatment of H-ARS, but neither of these medical countermeasures (MCM), nor any 
other efficacious mitigator to our knowledge, have shown efficacy against DEARE (Chua et 
al. 2014) (and unpublished).
Efficacy studies for H-ARS and DEARE must adhere to the criteria of FDA Animal Rule 
(AR) (Crawford 2002) and the recent FDA Guidance document (FDACDER 2015), drafted 
to guide drug development when human efficacy studies are unethical to perform. Suitable 
animal models of ARS and DEARE are essential for development of effective MCM against 
radiation. Such models can also provide valuable information regarding the natural history 
of ARS and DEARE, information that can be potentially exploited for development of new 
MCM, as well as better understanding of radiation effects on organ systems and the impact 
that MCM treatment for ARS may have on the severity and breadth of DEARE.
The authors have developed, extensively characterized, and validated murine models of H-
ARS in male and female C57BL/6 mice, and have used these models to study mechanisms 
and efficacy of MCM for FDA licensure under the Animal Rule for eventual stockpiling by 
the US government in the event of terrorist use of radiation (Plett et al. 2012; Plett et al. 
2015). Using these models, more than 200 studies testing the survival efficacy and dose/
schedule optimization of more than 70 MCM from the government and private industry have 
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been conducted over the past 13 years (Shakhov et al. 2012; Hoggatt et al. 2013; Plett et al. 
2014; Faller et al. 2017). Whenever possible, survivors of H-ARS are aged in our facility for 
up to 2.5 years of age and used to study the natural history of DEARE in radiation survivors, 
and the temporal occurrence of DEARE in different organs (Chua et al. 2012; Chua et al. 
2014; Unthank et al. 2015). Initial findings published in 2012 & 2014 documented severe 
hematopoietic dysfunction and loss of long-term HSC repopulating potential that persisted 
for up to 16–19 months (mo.) after exposure (the latest time point analyzed therein) (Chua et 
al. 2012). Subsequent studies documented the kinetics of fibrosis & dysfunction in non-
hematopoietic organs (heart, lung) in H-ARS C57BL/6 survivors up to 2 years of age 
(Unthank et al. 2015).
Ongoing H-ARS survival studies conducted over the past seven years using the authors’ 
consistent and reproducible murine model developed in young adult 3-month-old C57Bl/6 
mice, and continued aging of survivors from these H-ARS studies, have provided a unique 
opportunity to combine data from multiple similar studies into a composite dataset. This 
dataset is comprised of 38 H-ARS studies involving more than 1,500 mice initially exposed 
to lethal radiation on day 0, and 585 “day 30” survivors that were then enrolled in DEARE 
studies represented in this paper. H-ARS survivors were then analyzed for multiple 
hematopoietic parameters using sophisticated assays over the course of their lifetime. The 
large number of mice per experimental group reduced the inherent biological variability in 
radiation survivors, smoothing data curves and adding experimental rigor. These data are 
novel in that they are derived from a substantial number of mice of consistent age, gender, 
exposure parameters, husbandry, and to our knowledge, are the only such dataset of this 
magnitude. The mega-mouse study conducted at the Argonne National Laboratory between 
1972 to 1989 irradiated 49,000 mice, but those studies used a variety of exposure 
parameters, dose rates, types of radiation, geometries, and schedules (Wang et al. 2010; 
Haley et al. 2011), such that the number of mice in any particular group with consistent 
exposure conditions is much less than the 585 survivors mice in the current study. This 
publication further advances the understanding of and mechanisms surrounding 
hematopoietic DEARE and adds rigor and validity to our initial findings of persistent 
hematopoietic dysfunction in H-ARS survivors that arises at the level of the HSC / HPC and 
which affects all classes of hematopoietic cells for the life of the survivor.
MATERIALS AND METHODS
Mice and husbandry.
Specific pathogen-free C57BL/6 mice (50/50 male/female; Jackson Laboratory, Bar Harbor, 
Maine) were received at 10 weeks of age, an age analogous to a “young adult” human. All 
studies are performed on mice of the same age to avoid age-related changes in 
radiosensitivity (Grahn and Hamilton 1957; Grahn 1958; Yuhas and Storer 1967; Casarett 
1968). Weights ranged from 12.6–25.1gm for females and 18.3–30.7gm for males, with 
more than 95% of study mice falling between 15.0–23.4gm and 19.6–30.7gm, respectively. 
Mice were uniquely identified by ear punch and/or tail marks, and acclimatized for 2 weeks 
prior to irradiation at 12 weeks of age. Husbandry and health status monitoring were carried 
out as previously described (Plett et al. 2012). Mice were housed in microisolator cages and 
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provided with autoclaved acidified water in sipper tubes on days 1–30 post-irradiation and 
wet feed between days 4–30 post-irradiation. Irradiated mice were observed twice daily and 
scored on a scale of 0 to 3 for signs meeting the criteria for early euthanasia based on the 
severity of hunched posture, squinted/closed eyes, and activity (Plett et al. 2012). Mice with 
total scores of 8 or 9 underwent euthanasia by cervical dislocation or CO2 asphyxiation 
(Plett et al. 2012). All studies were approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee.
Recipient mice and donors of competitor cells used in competitive transplantation assays 
were of the congenic PtrcaPep3b/BoyJ (B6.BoyJ; CD45.1+) or the F1 hybrid of C57Bl/6 and 
B6.BoyJ mice (CD45.2+CD45.1+) strains. These two strains were used interchangeably as 
transplant recipients and competitor cell donors, and their leukocytes were distinguished 
from C57Bl/6 cells in transplant recipients by expression of CD45.1. B6.BoyJ and F1 hybrid 
mice were bred in-house and used between 8–12 weeks of age.
Study design.
Murine survivors from 38 MCM screening studies performed over a period of 7 years 
(2010–2016) were analyzed for DEARE. All studies and experiments reported in this paper 
are listed in Table 1, along with the year the study was conducted, the expected and actual 
LDXX/30, and the number of surviving mice that were then enrolled in DEARE studies. 
Non-irradiated age-matched controls are not documented in this table. Mice were exposed to 
total-body irradiation (TBI, LD50/30 to LD90/30) and treated with vehicle in MCM 
screening studies (referred to herein as “TBI-Veh”). Mice were randomized to treatment 
groups so that TBI-Veh mice and MCM-treated mice resided in the same cage. Non-
irradiated (NI) age- and sex-matched mice aged along with the TBI-Veh mice served as 
controls. Irradiated mice were assessed for health status for 30 days and euthanized when 
deemed moribund, as previously described(Plett et al. 2012). “Day 30” survivors were 
allowed to age in our animal facility for up to 30 mo. of age (27 mo. post-TBI). Subgroups 
of aging mice were euthanized at defined time points and assessed for residual bone marrow 
damage (RBMD) as described below. Some aging mice required humane euthanasia due to 
ulcerative dermatitis, labored breathing, severely hunched posture, inactivity, neurological 
symptoms or the presence of abnormal growths negatively affecting movement.
Irradiation and dosimetry.
Mice were placed in single chambers of a Plexiglas irradiation apparatus and were exposed 
to a single uniform total-body dose of gamma radiation between7.76 and 9.27 Gy from a 
137Cs radiation source (see Table 1 for estimated and actual LDXX/30 for all doses of 
radiation used in these studies). The dose rate over the 7 year period in which the studies 
were performed was 0.59 – 0.62 Gy min−1 for years 2010–2012 (GammaCell 40; Nordion 
International, Kanata, Ontario, Canada) or 0.93 – 1.03 Gy min−1 for years 2012–2016 (Mark 
1 Irradiator, JL Shepherd, San Fernando, CA). For irradiations utilizing the GammaCell 40 
irradiator, mice were exposed bilaterally on the dorsal and ventral sides, while in the Mark 
Irradiator, mice were rotated horizontally and exposed from a single source posteriorly and 
anteriorly.
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In-house dosimetry verified that dose homogeneity in the exposure field of the mice was 
0.0–4.3% of calculated central dose. To verify exposure doses, Landauer Inlight OSL 
nanodosimeters were placed in mouse phantoms and exposed along with the mice during all 
or select exposures in most studies. Nanodosimeters were read on a validated Landauer 
microStar reader calibrated with standard Dot dosimeters exposed with a NIST-traceable 
137Cs source (Battelle Memorial Institute, WA). Reproducibility of individual dots was 
3±1% with accuracy of 4±2%. Dose output checks (using farmer-type ion chambers and a 
validated electrometer), and dose field uniformity checks by exposing film, are performed 
periodically by an onsite medical physicist.
TBI-Vehicle mice.
TBI-Veh mice used in these studies previously served as controls for H-ARS MCM 
screening studies and were thus administered appropriate vehicle solutions using an identical 
administration route and schedule as that of the MCM under evaluation in each study. 
Volumes, routes, and composition of vehicle solutions used in studies presented herein are as 
follows: 50 uL for intramuscular and 94 to 128 uL for subcutaneous injections and oral 
gavages. Vehicle solutions consisted of: 20 mM Tris, pH 7.5, 200 mM NaCl, 10% glycerol; 
or 0.05% Tween-20; PlasmaLyte A solution; or 10 mM sodium acetate, pH 4.8, 140 mM 
NaCl; or 10 mM sodium acetate, 5% sorbitol, 0.003% polysorbate 20, pH 4.0; 160mmol/L 
sodium chloride solution (Normal saline; 0.9% NaCl, w/v); or 10 mM sodium phosphate, 
4% mannitol, 1% sucrose pH 6.2; or Dextrose 5% in water (D5W); or 5% DMSO 
Polyethylene glycol (PEG)-200; or 10% EtOH Sesame oil: Cremophor RH40 (55:35 w/w); 
or 20 mM sodium phosphate monobasic; or 1% sucrose and 4% D-mannitol in Water for 
Injection, pH 6.5±0.1; or 50mmM Citrate buffer pH4-4.4; or empty liposomes; or 0.9% 
saline (w/v) + 0.1% bovine serum albumin (BSA) solution; or 5% (D)-Glucose solution; or 
sodium acetate (10 mM), mannitol (45 mg mL−1), polysorbate 20 (0.05 mg mL−1), pH 4.0; 
or 10 mM sodium phosphate, 4% mannitol, 1% sucrose pH 6.2.
Residual bone marrow damage studies.
TBI-Veh mice which survived H-ARS, along with non-TBI age-matched controls, were 
assessed at various times up to 30 mo. of age (27 mo. post-TBI) for body weight, complete 
blood count (CBC), bone marrow (BM) cellularity, hematopoietic progenitor number, 
primitive hematopoietic progenitor phenotypes, cell cycle analyses, and HSC multilineage 
reconstitution potential in competitive transplantation assays, all as previously described 
(Chua et al. 2012; Chua et al. 2014).
Suspension cultures were initiated with phenotypically-defined BM cells isolated from TBI-
Veh mice at 4 mo. or 8 mo. post-LD70/30 (872 cGy). Briefly, BM cells were enumerated, 
stained with fluorescently conjugated antibodies, and isolated by flow cytometric cell sorting 
to yield lineage-negative (CD3, B220, Gr1) cells of the following subgroups: Sca-1+, 
Sca-1−, cKit+, cKit−, CD150+, and CD150−. Purified cells from 3 mice per treatment group 
(TBI-Veh or age-matched NI controls) were pooled and 900 to 3 × 105 cells per well used to 
initiate suspension cultures in 5% CO2 in 100%-humidified air. Media consisted of Iscove’s 
Modified Dulbecco’s Medium (IMDM) supplemented with 20% fetal bovine serum (FBS), 
59 uM 2-mercaptoethanol, 10 ng/mL murine stem cell factor (mSCF, PeproTech), 50 ng/mL 
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murine FMS-related tyrosine kinase 3 ligand (mFlt3L, eBioscience), 20 ng/ml murine 
megakaryocyte-derived growth factor/thrombopoietin (mMDGF/TPO, Peprotech), 10 ng/ml 
murine interleukin-3 (mIL-3, STEMCELL Technologies), and 25 ng/mL human 
interleukin-6 (hIL-6, STEMCELL Technologies). Cytokines were delivered every other day 
and cells enumerated weekly. Cultures were visualized daily for confluence, and demi-
depopulated as needed to maintain confluence below 90–100%.
Statistical analyses.
The Student’s unpaired t-test was used to compare the following parameters: body weight, 
CBC parameters, BM cellularity, percent and number of BM primitive hematopoietic cells 
per mouse, cell cycle status, and donor chimerism. While many parameters measured over 
time were also significantly different at individual time points, a single asterisk denoting 
significance comparing all mice over time was used rather than multiple asterices at 
individual time points, for the ease of the reader.
RESULTS
Body weights and CBC.
Body weights and CBC were documented for up to 30 mo. of age (27 mo. post-TBI) in H-
ARS survivors from 38 studies conducted over the past 7 years. Data were pooled and in 
agreement with our earlier studies conducted with fewer mice (Chua et al. 2012), the 
compilation data showed significantly decreased body weight in H-ARS survivors compared 
with NI, which becomes more dissimilar as the mice age (Fig. 1A). The concentrations of 
white blood cells (WBC, Fig. 1B), neutrophils (NE, Fig. 1C), lymphocytes (LY, Fig. 1D), 
red blood cells (RBC, Fig. 1E), and platelets (PLT, Fig. 1F) of TBI-Veh mice were all 
significantly less than those in NI age-matched controls over time. The number of LY in 
TBI-Veh mice was approximately half the value of NI mice, and the most disparate of CBC 
values between TBI-Veh and NI. The larger difference in the number of LY between TBI-
Veh and NI mice (Fig. 1D) compared to NE (Fig. 1C) illustrated the myeloid skew that 
occurred in irradiated survivors, as we and others have shown (Morrison et al. 1996; Kim et 
al. 2003; Chua et al. 2012).
Bone marrow (BM) cellularity and primitive hematopoietic phenotypes.
Similar to CBC, all classes of BM hematopoietic cells were also significantly decreased in 
TBI-Veh mice compared to NI (Fig. 2) in this comprehensive dataset. The total number of 
BM cells in TBI-Veh mice was significantly decreased compared to that in NI age-matched 
controls (Fig. 2A), similar to our previous data from a smaller set of studies (Chua et al. 
2012). While the percentage and absolute number of KSL cells were significantly decreased 
in TBI-Veh mice (Figs. 2B and 2C), the percentage of KSL CD150+ cells was significantly 
increased over time (Fig. 2D), due to the increased expression of CD150 on hematopoietic 
cells after irradiation as we (Chua et al. 2012) and others (Simonnet et al. 2009) have 
reported. The increased expression of CD150 on KSL from TBI-Veh mice did not, however, 
result in increased number of KSL CD150+ in TBI-Veh mice (Fig. 2E) due to the 
significantly decreased numbers of the parent population, KSL.
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Cell cycle analyses.
The authors previously demonstrated reduced hematopoietic stem cell engraftment potential 
and increased cell cycle activity in KSL CD150+ cells isolated from BM of TBI-Veh mice 
compared to similar cells from NI age-matched controls (Chua et al. 2012), indicating loss 
of key functional characteristics of HSC. These findings were further substantiated in this 
comprehensive analysis of 38 experiments conducted over the past 7 years. The percentage 
of TBI-Veh KSLCD150+ cells in G0/G1 at different times post-exposure was found to be 
significantly lower over time compared to NI KSLCD150+ cells (Fig. 2F), indicating 
significantly increased cell cycling and loss of mitotic quiescence.
HSC long-term engraftment potential.
This comprehensive analysis further demonstrated the inability of phenotypically-defined 
KSL CD150+ cells isolated from bone marrow of TBI-Veh mice to reconstitute multi-
lineage hematopoiesis in competitive transplantation experiments, the only true test of HSC 
content (Fig. 3). Loss of HSC potential was evident as early as one month post-TBI all the 
way to 27 mo. post-TBI (Fig. 3). Significant loss of lymphoid repopulating potential in favor 
of myeloid reconstitution was observed in transplant recipients (data not shown), as the 
authors’ have previously shown (Chua et al. 2012; Chua et al. 2014). Fig. 3 also illustrates 
the loss in engraftment potential of HSC from naïve NI mice that occurred naturally with 
aging (Morrison et al. 1996; Kim et al. 2003; Kamminga et al. 2005; Nijnik et al. 2007; 
Rossi et al. 2007; Rube et al. 2011; Snoeck 2013; Behrens et al. 2014).
Retention of cell surface HSC phenotype in TBI-Veh mice.
A potential concern with regards to our observation of severely diminished HSC 
repopulation potential of phenotypically-defined KSL CD150+ cells from TBI-Veh mice 
was the possibility that the HSC cell surface phenotype may have changed after irradiation, 
such that cKit, Sca-1, or CD150 may no longer be expressed on HSC from H-ARS 
survivors. A precedent for this notion is the temporary loss of cKit on HSC isolated within 
days from irradiated mice (Shen et al. 2004). To define the cell surface phenotype of HSC 
from TBI-Veh mice, lineage-negative cells from TBI-Veh mice at 8 mo. post-TBI were 
subdivided into Sca-1+ and Sca-1-cells, cKit+ and cKit-cells, and CD150+ and CD150-cells 
by flow cytometric cell sorting. These 6 populations were assayed for proliferative potential 
(in comparison to similar cells isolated from age-matched NI controls) in cytokine-
supplemented suspension cultures as a measure of primitive hematopoietic potential. For 
each of the three markers, cultures from both NI and TBI-Veh cells initiated with the 
phenotype known to be expressed on long-term HSC (i.e., lin− Sca-1+, lin− cKit+, lin− 
CD150+) produced more cells than cultures initiated with lin− Sca-1−, lin− cKit−, or lin− 
CD150− (Figs 4A, 4B, and 4C). Not surprisingly, proliferative potential of cells from NI 
mice was generally higher than similar populations isolated from TBI-Veh mice. The 
positive phenotype (lin− Sca-1+, lin− cKit+, and lin− CD150+) from both NI (Fig. 4D) and 
TBI-Veh (Fig. 4E) mice also produced a greater number of hematopoietic colonies than the 
corresponding negative phenotype.
To further validate these findings, the long-term term repopulating potential of lin- CD150+ 
and lin- CD150− isolated from TBI-Veh mice was examined in competitive transplantation 
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assays in comparison to similar cells from NI mice. As expected, lin- CD150+ cells isolated 
from NI mice demonstrated predictably robust and sustained donor chimerism of between 
40–60%, indicative of HSC activity (Fig. 4F). The TBI-Veh lin- CD150+ population showed 
initial donor chimerism at 1 month post-transplant of ~35%, however, this was not sustained 
and decreased to ~10% for the remainder of the 6 month period. Chimerism in mice 
transplanted with lin- CD150- cells from both NI and TBI-Veh mice was significantly less 
than chimerism in mice transplanted with lin- CD150+ cells (Fig. 4F). These data strongly 
suggested that the HSC phenotype, with respect to CD150 expression, in TBI-Veh mice was 
the same as in naïve non-irradiated mice, namely CD150+. The transient donor chimerism 
suggested the presence of short-term repopulating progenitors within the TBI-Veh lin- 
CD150+ population and lack of long-term engrafting HSC, in agreement with our previous 
findings (Chua et al. 2012).
We have also transplanted whole bone marrow (WBM) in comparison to purified KSL 
CD150+ cells from TBI-Veh mice and have shown similar diminished engraftment potential 
of WBM as that observed with KSL CD150+ cells in Fig. 3, further substantiating that there 
were very few cells of any phenotype with long-term engraftment potential in the marrow of 
TBI-Veh mice (data not shown).
Lineage reconstitution in recipients of TBI-Veh lin- CD150+ cells was skewed toward the 
myeloid lineage, similar to the myeloid skewing previously reported for KSLCD150+ cells 
isolated from TBI-Veh mice (Fig. 4G) (Chua et al. 2012). Lineage reconstitution data could 
not be obtained for mice transplanted with lin- CD150- cells, as the low donor chimerism 
did not allow lineage assessment. Interestingly, the NI lin- CD150- population showed a 
similar profile of multi-lineage reconstitution as observed for the NI lin- CD150+ population 
(Fig. 4G) and F1 competitor cells (Fig. 4H), indicating that while stem cell potential was 
low in NI lin- CD150- cells, multi-lineage reconstitution potential was retained, in 
agreement with Weksberg et. al. (Weksberg et al. 2008). Taken together, these data strongly 
suggest that HSC in TBI-Veh mice continue to express cKit, Sca-1, and CD150, just as HSC 
in NI mice, albeit severely depleted of functional HSC activity compared to NI controls.
DISCUSSION
The data reported herein represent a composite analysis of more than 38 H-ARS studies 
conducted over seven years, most of which were screening studies for survival efficacy of 
candidate medical countermeasures according to the FDA’s Animal Rule. These studies 
utilized more than 1,500 initial vehicle-treated control mice exposed to doses of radiation 
ranging from the LD50/30 to the LD90/30, and 585 day-30 survivors that were then aged in 
our animal facility for examination of the delayed effects of acute radiation exposure 
(DEARE) affecting the hematopoietic system. These data expand upon earlier publications 
generated with smaller group sizes and datasets (Chua et al. 2012; Chua et al. 2014), and 
provide increased power and rigor to our observation of a permanent defect in hematopoiesis 
originating at the level of the hematopoietic stem cell (HSC). Radiation-induced HSC 
dysfunction in survivors of lethal radiation exposure affected the two hallmarks properties of 
HSC, namely self-renewal and multilineage differentiation capability, manifesting as 
significantly reduced production of blood cells and premature prominent myeloid skewing.
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The novel aspect of these data is the substantial dataset from which they were derived. 
Examinations of DEARE in survivors of lethal radiation exposure are difficult to conduct, 
primarily due to expense of long-term animal care and the need for large numbers of animals 
for statistically meaningful data. Retrospective analysis of unrelated studies from multiple 
investigators are often not a feasible option due to difficulty understanding the effect that 
differing exposure parameters and husbandry may have on DEARE outcomes. The mega-
mouse experiments conducted at Argonne National Laboratory from 1972 to 1989 irradiated 
49,000 mice (Wang et al. 2010; Haley et al. 2011), but differences in radiation geometry, 
fractionation schedules, type, and dose rate in subgroups prevented analyses of a dataset as 
large as the current study. Human data are even more difficult to examine. The most 
extensively studied human data are derived from survivors of the atomic bombings in 
Hiroshima and Nagasaki, but confounding factors such as age and nutritional status at time 
of exposure, range of doses received, radiation quality, and difficulties in determining 
exposure dose and exposure geometry make correlations of disease risk and radiation 
exposure difficult (Little 2009). In apparent contrast to our data, Kyoizumi et. al (Kyoizumi 
et al. 2016) showed seeming recovery of hematopoietic stem and progenitor cells in atomic 
bomb survivors. However, the doses received by the atomic bomb survivors were likely sub-
lethal (albeit still damaging), allowing some recovery of hematopoietic stem and progenitor 
cells, while the doses of radiation received by mice in the current studies were in the lethal 
range (LD50/30-LD90/30). Other studies have shown possible reductions in self renewal 
capability of hematopoietic stem / progenitor cells secondary to dose-dependent DNA 
damage (Kajimura et al. 2016), in agreement with our studies showing loss of HSC 
repopulating potential in competitive transplantation assays which does not recover for the 
life of the mouse. Others have documented detriments in immune function in atomic bomb 
survivors (Kusunoki and Hayashi 2008), similar to our studies showing severe myeloid skew 
and a relative decrease in circulating lymphocytes much greater than that of other 
hematopoietic lineages in irradiated mice. The myeloid skew observed in irradiated mice 
illustrated the loss of multilineage differentiation potential of HSC from irradiated survivor 
mice.
A potential concern in our examinations of HSC multilineage engraftment potential of bone 
marrow KSL CD150+ cells from irradiated survivor mice is that, had the phenotype of HSC 
changed in irradiated survivors, then assaying KSL CD150+ cells as the “HSC phenotype” 
may have been in error. A precedent for a change in the HSC phenotype after irradiation lies 
in the observation of significant downregulation of cell surface cKit on HSC after irradiation 
(Shen et al. 2004) and (unpublished observations), likely due to local environmental factors 
in the irradiated bone marrow niche. While expression of cKit eventually returned on HSC 
exposed to an irradiated microenvironment, this did not preclude changes in other cell 
surface markers that may alter the phenotype of HSC from irradiated mice long after 
exposure. To this point, expression of CD150 is remarkably upregulated on KSL cells from 
irradiated survivor mice for life as we (Chua et al. 2012) and others (Simonnet et al. 2009) 
have documented. To ensure that interrogating KSL CD150+ cells for HSC potential was not 
pursuing the wrong HSC phenotype, we examined hematopoietic function of lineage-
negative cells subdivided based on expression or lack thereof of Sca-1, cKit, or CD150. In 
agreement with the documented HSC phenotype of lineage-negative Sca-1+ cKit+ CD150+ 
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in non-irradiated naïve mice, cells from irradiated survivors expressing these markers 
performed better in all hematopoietic assays compared to their counterparts lacking 
expression, substantiating the assumption that the definition of KSL CD150+ as the 
phenotype of long-term repopulating HSC does not change in survivors of lethal radiation 
exposure.
CONCLUSION
A compilation of 38 similar H-ARS studies conducted over a seven-year period in the 
authors’ laboratory, comprising more than 1,500 irradiated young adult C57BL/6 mice and 
nearly 600 day-30 survivors, was assessed for hematopoietic DEARE at various times up to 
30 months of age. This large dataset adds rigor and validity to our findings of persistent 
hematopoietic dysfunction in H-ARS survivors that arises at the level of the hematopoietic 
stem cell and which adversely affects all classes of hematopoietic cells for the life of the 
survivor.
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Figure 1. Body weight and CBC profiles in TBI-Veh and NI mice.
TBI-Veh and NI mice were assessed at various times up to 27 mo. post-irradiation for body 
weight (panel A), and up to 21 mo. post-irradiation for CBC, including white blood cells 
(WBC, panel B), neutrophils (NE, panel C), lymphocytes (LY, panel D), red blood cells 
(RBC, panel E), and platelets (PLT, panel F). Blood for CBC was obtained by tail snips and 
assayed using a Hemavet system (Drew Scientific, Waterbury, CT). Lines represent mean ± 
SEM; * p < 0.01 comparing TBI-Veh to NI age-matched controls. The number of mice 
analyzed for body weight and CBC at each time point are given below panels A and B, 
respectively.
Chua et al. Page 14
Health Phys. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Bone marrow (BM) cellularity, and primitive hematopoietic phenotypes in TBI-Veh 
and NI mice.
TBI-Veh and NI mice were assessed at various times up to 21 mo. post-irradiation for total 
number of BM cells / mouse (BM cellularity, panel A), and up to 18 mo. post-irradiation for 
primitive hematopoietic populations, including percentage of BM cKit+ Sca-1+ lin- cells 
(KSL cells, panel B), the absolute number of KSL cells / mouse (panel C), the percentage of 
KSL CD150+ cells (KSLCD150+, panel D), the absolute number of KSLCD150+ cells / 
mouse (panel E), and the cycling activity of KSLCD150+ cells (panel F). The absolute 
number of BM cells per mouse was calculated based on cell counts from LDBM or WBM 
samples. BM cells were stained for cell surface hematopoietic stem cell markers, Sca-1, 
cKit, lineage markers (CD3, B220, Gr1) and CD150, and analyzed by flow cytometry for 
primitive hematopoietic populations. BM cells that were surface stained for hematopoietic 
stem cell markers were fixed and then stained with the DNA stain DAPI and analyzed for 
cell cycle activity by flow cytometry. Lines represent mean ± SEM; * p < 0.05 comparing 
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TBI-Veh to non-irradiated age-matched controls. The number of mice analyzed for BM 
cellularity are shown below panel A; the number of mice analyzed for all other parameters 
are shown below panel B.
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Figure 3. Long-term engraftment potential of primitive hematopoietic populations in TBI-Veh 
and NI mice in competitive transplantation assays.
TBI-Veh and NI mice were assessed at various times up to 27 mo. post-irradiation for long-
term engraftment potential of primitive KSLCD150+ cells. Lethally irradiated congenic 
murine recipients were transplanted with 150 KSLCD150+ donor cells, along with 1–2×105 
LDBM competitor cells of congenic origin. Peripheral blood samples from tail-snips were 
obtained from transplanted recipients and analyzed by flow cytometry to determine donor 
chimerism using antibodies against CD45.1 and CD45.2. Lines represent mean ± SEM; * p 
< 0.01 comparing TBI-Veh to non-irradiated age-matched controls. The number of donor 
and recipient mice at each time point are given below the figure.
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Figure 4. Retention of steady state HSC cell surface markers in TBI-Veh mice.
Sca-1+ and Sca-1− lineage-negative (lin-) cells (panel A), cKit+ and cKit− lin- cells (panel 
B), and CD150+ and CD150- lin- cells (panel C) were isolated from NI and TBI-Veh mice 
at 8 mo. post-TBI and used to initiate suspension cultures in IMDM plus 20% FBS, 59 uM 
2-mercaptoethanol, mSCF, mFlt3L, mMDGF/TPO, mIL-3, and hIL-6. Cultures were demi-
depopulated as needed and cells enumerated weekly. Data are fold-change in cell number 
from the initial cell number (900 to 3 × 105/well), used to initiate cultures on day 0, and are 
representative of two experiments with similar results (the 2nd experiment used cells from 
TBI-Veh mice at 4 mo. post-TBI). When data on day 8 from all 3 cultures are pooled 
together, cell number of the “positive” phenotype (Sca- 1+, cKit+, and CD150+) of the NI 
and the positive phenotypes of the TBI-Veh are significantly increased compared to their 
respective negative phenotypes (Sca-1-, cKit-, and CD150-); p≤0.0111. Cells from NI mice 
(panel D) and TBI-Veh mice (panel E) used to initiate cultures in panels A, B, and C were 
Chua et al. Page 18
Health Phys. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
also examined for hematopoietic progenitor cells in standard methylcellulose assays. Data in 
panels D and E are the mean number of colonies per 2,500 cells from 2 experiments initiated 
with cells from TBI-Veh mice at 4 mo. and 8 mo. post-TBI. Brackets indicate significant 
differences (p<0.05) in total number of progenitors. Panel F shows monthly donor-derived 
chimerism in competitive transplantation assays in mice transplanted with lin- CD150+ cells 
or lin- CD150− cells isolated from NI mice or TBI-Veh mice 9.4 mo. post-8.72 Gy. 1.3 × 
104 cells from a pool of 2 donors were transplanted into recipient mice (n=2 recipients for 
the NI CD150+ group; n=3 recipients for all other groups) along with 2 × 105 competitor 
cells. *p<0.01 comparing TBI-Veh lin- CD150+ with TBI-Veh lin- CD150-, and NI lin- 
CD150+ with NI lin- CD150-. Panel G shows donor lineage reconstitution in peripheral 
blood at 6 mo. post-transplant of the mice in panel F. Data in panel G represent the 
percentage of donor CD8+ (8), CD4+ (4), B220+ B cells (B), and Gr-1+ granulocytes (G), 
expressed as a percentage of total donor cells. Panel H shows lineage reconstitution by the 
congenic competitor cells (expressed as a percentage of total competitor cells) that were co-
transplanted with cells from NI or TBI-Veh mice and which acts as an internal standard for 
normal lineage reconstitution.
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